Cell Viability Assays Market Overview:

The Cell Viability Assays Market size is estimated to reach $2.8 Billion by 2030, growing at a CAGR of 8.6% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Cell Viability Assays Market – By Product (Reagents & Assay Kits, Instruments), By Cell Type (Human Cells, Animal Cells, Microbial Cells, Plant Cells), By Cell Technology (Colorimetric Assays, Fluorometric Assays, Luminescent Assays, High-Content Screening, Others), By Assay Type (Cytotoxicity Assays, Cell Proliferation Assays, Apoptosis Assays, Necrosis Assays, Cell Senescence Assays, Cell Migration, Chemotaxis Assays, Others), By Detection Method (Absorbance-based Assays, Fluorescence-based Assays, Chemiluminescence-based Assays, High-Content Screening, Others), By Application (Drug Discovery & Development, Stem Cell Research, Basic Research, Clinical Diagnostics, Toxicology Testing, Personalized Medicine, Others), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), Hospitals & Diagnostic Laboratories), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”

Rising chronic diseases are boosting the demand for Cell Viability Assays. Advancements in biotechnology are driving the adoption of these assays. The growing focus on regenerative medicine and stem cell research is further fueling market growth. Additionally, increased R&D investments are accelerating the development and use of Cell Viability Assays during the forecast period.

North America Dominated the Market in 2023:

North America accounted for the largest share of 35% of the Cell Viability Assays Market in 2023. North America dominates the Cell Viability Assays market owing to higher healthcare accreditations, robust biotechnology industry, and higher research spending. This means that the region is iconic to big industry players including ThermoFisher that indicated that 53% of its revenue in the fiscal year 2023 was adapted from North America, further reinstating the regions’ superiority. Also, high implementation rates of modern scientific and technical achievements, as well as the increasing interest in regenerative medicine and personalized healthcare also play a role in North America to dominate the Cell Viability Assays market.

Cell Viability Assays Market: Key Takeaways

Technological Advancements:

Technological innovations are a key driver in the Cell Viability Assays market since they enhance the efficiency, reliability and speed of the process. For example, Promega’s RealTime-Glo™ MT Cell Viability Assay enables the scientists to assess the cell wellness leisurely for 72 hours with no need of washing or replacing the media of the cell. This makes the research process easier and has a way of offering more credible and current data as well. Such advancements enable efficiency in the discovery of drugs and diseases and therefore play the role of technology in the growth of the market.

For More Queries About "Cell Viability Assays Market " @ https://www.industryarc.com/Research/Cell-Viability-Assays-Market-Research-505598

Rising Chronic Diseases:

The growth of chronic disorders is the main factor influencing the Cell Viability Assays market as such diseases require better diagnostic and treatment methods. Long-term diseases such as cancer, diabetes, as well as cardiovascular diseases can take a long time to find and develop drugs to treat them, where cell viability assays are essential. For instance, a report from the Australian Institute of Health and Welfare dated July 2024 showed that in 2022, 90% of deaths in Australia were as a result of chronic diseases thus highlighting the increasing health cost burden in the future. 

Scope of the Report: 

Report Metric

Details

Base Year Considered

2023

Forecast Period

2024–2030

CAGR

8.6%

Market Size in 2030

$2.8 Billion

Segments Covered

By Product, By Cell Type, By Cell Technology, By Assay Type, By Detection Method, By Application, By End User and By Geography.

 

Geographies Covered

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Netherland and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa).

Key Market Players

1. Thermo Fisher Scientific

2.      Merck Group

3.      Promega Corporation

4.      Bio-Rad Laboratories

5.      Abcam

6.      Agilent Technologies

7.      BD Biosciences

8.      PerkinElmer

9.      Danaher Corporation

10.   Enzo Life Sciences



Recent Developments:
  1. In June 2024, Promega launched the MyGlo™ Reagent Reader, a compact device specifically equipped for 96-well plate luminosity-based cell viability tests. The integrated instrument reduces the requirements to share instruments and address the complexity of data, in addition to providing step-by-step instruction for performing CellTiter-Glo® assays without prior instructions. 
  2. In April 2024, MilliporeSigma introduced the Aptegra™ CHO genetic stability assay, which is the first and only all-in-one validated test. This innovation helps in streamlining the genetic stability testing process for the industry.
  3. In March 2023, Bayer and Thermo Fisher Scientific entered into a partnership to bring next-generation sequencing (NGS) based companion diagnostic assays (CDx) to market. These assays will use Thermo Fisher’s NGS platform to accurately pinpoint patients for Bayer’s precision cancer medicines. 

Cell Viability Assays Market: Competitive Landscape

Key companies profiled in the Cell Viability Assays Market are Thermo Fisher Scientific, Merck Group, Promega Corporation, Bio-Rad Laboratories, Abcam, Agilent Technologies, BD Biosciences, PerkinElmer, Danaher Corporation, Enzo Life Sciences and others.

Related Reports:

Specialty Drug Distribution Market- Specialty Drug Distribution Market is projected to reach $747.6 million by 2027 at a CAGR of 13.5% during the forecast period 2022-2027, driven by the increasing demand for specialized drugs and advancements in distribution networks.

Biopharmaceutical Market- Biopharmaceutical Market is projected to reach $532.2 billion by 2027 at a CAGR of 7.1% during the forecast period 2022-2027, fueled by increasing investments in biopharmaceutical research and development and the growing demand for biologics.

Anti-Aging Products & Therapies Market- Anti-Aging Products & Therapies Market size is forecast to reach $93.2 billion by 2027, after growing at a CAGR of 7.72% during 2022-2027. The market is driven by increasing consumer awareness about skincare, rising demand for non-invasive treatments, and advancements in product formulations.

About IndustryARC™:

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.

Contact Us:

Mr. Venkat Reddy
IndustryARC
USA: (+1) 518-282-4727